Paris-based Jeito Capital, a PE fund centered on biopharma innovation, has furthered its place as a participant in international healthcare funding with two main contributions to clinical-stage biotech corporations Aviceda Therapeutics and XyloCor Therapeutics – totalling over €264 million.
Jeito’s present portfolio providing is valued at €534 million, with a deal with a patient-focused method and on financing the event and development of “ground-breaking” medical innovation.
Jeito lately participated within the upsized €199.6 million Collection C financing spherical for Aviceda Therapeutics, the financing spherical was co-led by Omega Funds and TCGX, with participation from Enavate Sciences, Blue Owl Healthcare Alternatives, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Administration, funds managed by abrdn Inc., and Digitalis Ventures.
The Massachusetts-based biotech firm is advancing using superior immunomodulators, together with its lead candidate AVD-104 for geographic atrophy secondary to age-related macular degeneration. Jeito stood out as the only real European fund among the many syndicate of institutional buyers.
The funding will bolster Aviceda’s late-stage scientific trials for AVD-104, a next-generation remedy demonstrating twin mechanisms of motion that concentrate on immune modulation and complement inhibition. Already, AVD-104 has proven promise in lowering lesion development and enhancing visible perform in earlier trials.
This financing may also help Aviceda’s growth into different ophthalmic indications, because it anticipates pivotal 12-month endpoint knowledge in late 2025.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital stated: “Our funding in Aviceda Therapeutics completely illustrates our ambition to champion promising late-clinical stage biopharma with the potential to grow to be international market leaders that may make a significant distinction in affected person lives. Now we have been impressed by Aviceda’s new mechanism whose first constructive outcomes symbolize a brand new hope for sufferers. We stay up for beginning this new collaboration and bringing our European experience and international method to speed up this transformative remedy for sufferers with excessive unmet wants.”
Additional emphasising its experience in biopharma, Jeito led a €64.9 million Collection B financing spherical for Pennsylvania-based XyloCor Therapeutics, a clinical-stage firm on the forefront of gene remedy for heart problems.
Current institutional buyers, together with EQT, Fountain Healthcare Companions, and Lumira Ventures, additionally participated within the spherical. Rachel Mears, Associate at Jeito Capital, may also be a part of XyloCor Board of Administrators.
This funding will assist two Section 2 trials for its lead asset, XC001, geared toward treating refractory angina and as an adjunctive remedy in coronary artery bypass graft surgical procedure. The method, leveraging endocardial administration and focused angiogenesis, holds the potential to handle the unmet wants of cardiovascular sufferers with restricted remedy choices.
Rachel Mears added: “We’re thrilled to assist XyloCor because it advances its scientific trials to judge XC001 as a possible remedy for sufferers scuffling with the burden of heart problems. The corporate has robust assist from an skilled management group, world-class cardiologists and scientists and has made spectacular achievements in a short while in advancing its novel gene remedy method. We stay up for collaborating with the corporate because it progresses to the subsequent steps in its scientific programme.”
These investments spotlight Jeito’s strategic deal with high-impact therapeutic areas, together with ophthalmology and cardiology, in addition to following the latest acquisition of portfolio firm EyeBio by Merck & Co for as much as €2.8 billion.
Jeito’s twin presence in Europe and america could place it to bridge these healthcare markets, leveraging its experience to foster cross-continental collaborations.